|
|
A-910823 |
|
Vaxjo ID |
144 |
|
Vaccine Adjuvant Name |
A-910823 |
|
Adjuvant VO ID |
VO_0006103
|
|
Description |
An emulsion vaccine adjuvant that is squalene-based adjuvant, induces T follicular helper cells and humoral immune responses via alpha-tocopherol component |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
Japan |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Monkey |
|
Components |
squalene and α-tocopherol |
|
Storage |
2-8C, protect from light |
|
Preparation |
oil in water emulsion using high-pressure homogenization |
|
Function |
Type: emulsion vaccine adjuvant. Induces Th1-biased immune profile. Strong induction of antibodies, T follicular helper (Tfh) cells, and germinal center B (GCB) cells |
| References |
(Takeuchi, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=90]
Hashimoto et al., 2022: Hashimoto M, Aoe S, Kawazu Y, Seki NM, Hashimoto K, Yoshihara K, Homma T, Sonoyama T, Omoto S. Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques. Vaccine. 2022; 40(52); 7520-7525. [PubMed: 36372670].
Iwata et al., 2022: Iwata S, Sonoyama T, Kamitani A, Shibata R, Homma T, Omoto S, Igarashi K, Ariyasu M. Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings. Vaccine. 2022; 40(27); 3721-3726. [PubMed: 35606235].
|
|
